## Programme, Thursday 12 November 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 08.35</td>
<td><strong>Welcome by the ESUI</strong></td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>08.35 - 09.00</td>
<td><strong>News from the ESUI</strong></td>
<td>Chair: J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>08.35 - 08.40</td>
<td>Results from the ESUI and EAU guideline office joint committee</td>
<td>T. Loch, Flensburg (DE)</td>
</tr>
<tr>
<td>08.40 - 09.00</td>
<td><strong>Standard operating procedures for ultrasound examinations</strong></td>
<td></td>
</tr>
<tr>
<td>08.40 - 08.50</td>
<td>Genital organs: Prostate and testis</td>
<td>P. Martino, Bari (IT)</td>
</tr>
<tr>
<td>08.50 - 09.00</td>
<td>Urinary tract: Kidney and bladder</td>
<td>C. Trombetta, Trieste (IT)</td>
</tr>
<tr>
<td>09.00 - 10.20</td>
<td><strong>Imaging and individualised medicine in urology</strong></td>
<td>Moderators: P.A. Geavlete, Bucharest (RO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Ritter, Mannheim (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H. Thoeny, Berne (CH)</td>
</tr>
<tr>
<td></td>
<td>All presentations are 10 minutes in length, followed by 5 minutes of discussion.</td>
<td></td>
</tr>
<tr>
<td>09.00 - 09.15</td>
<td>Bladder cancer staging with MRI: Can we finally stage correctly?</td>
<td>T. El Diasty, Mansoura (EG)</td>
</tr>
<tr>
<td>09.15 - 09.30</td>
<td>3D vascular anatomy for partial nephrectomy: How to do it and how it improves selective clamping?</td>
<td>M. Gallucci, Rome (IT)</td>
</tr>
<tr>
<td>09.30 - 09.45</td>
<td>Stone characterisation with imaging and how to fine-tune stone treatment</td>
<td>M. Ritter, Mannheim (DE)</td>
</tr>
<tr>
<td>09.45 - 10.00</td>
<td>Functional imaging of the kidney and how it helps to individualise management</td>
<td>M. Notohamiprodojo, Tübingen (DE)</td>
</tr>
<tr>
<td>10.00 - 10.15</td>
<td><strong>NBI, PDD and SPIES in individualised treatment of upper urinary tract urothelial cancer</strong></td>
<td>O. Traxer, Paris (FR)</td>
</tr>
<tr>
<td>10.15 - 10.20</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>10.20 - 10.50</td>
<td><strong>Coffee break and poster viewing</strong></td>
<td></td>
</tr>
</tbody>
</table>
10.50 – 11.50  **New imaging technologies on the horizon**

*Moderators:*  M. Ferreira Coelho, Lisbon (PT)
C. Trombetta, Trieste (IT)
A. Villers, Lille (FR)

**All presentations are 7 minutes in length, followed by 3 minutes of discussion.**

10.50 – 11.00  Radio Immuno Guided Surgery (RIGS) in urology
S. Siracusano, Trieste (IT)

11.00 – 11.10  High resolution ultrasound in urology
C. Pavlovich, Baltimore, Maryland (US)

11.10 – 11.20  Super-fast ultrasound in urology
M. Tanter, Paris (FR)

11.20 – 11.30  7T MRI in urology: Are high field strengths ready for practice?
T.W.J. Scheenen, Nijmegen (NL)

11.30 – 11.40  Iron nanoparticles: Are they back on the block?
T.W.J. Scheenen, Nijmegen (NL)

11.40 – 11.50  Questions and answers

11.50 – 13.00  **Lunch symposium**

13.00 – 14.30  **Molecular imaging in Urology: Joint sessions of the EAU Section of Urological Imaging (ESUI) and the European Association of Nuclear Medicine (EANM)**

*Moderators:*  A. Briganti, Milan (IT)
S. Fanti, Bologna (IT)
J. Walz, Marseille (FR)

**All presentations are 10 minutes in length, followed by 5 minutes of discussion**

13.00 – 13.25  **Point and counterpoint in prostate cancer:**
*Does PET really change the management of prostate cancer?*

13.00 – 13.10  Yes, it does:  R. Schiavina, Bologna (IT)

13.10 – 13.20  No, it does not:  L. Budäus, Hamburg (DE)

13.20 – 13.25  Discussion

13.25 – 13.40  Ultrasound and molecular imaging
H. Wijkstra, Amsterdam (NL)

13.40 – 13.55  **The best PET tracer for prostate cancer:** FACBC, PSMA, 18F-Choline, 11C-Choline, ...?
S. Fanti, Bologna (IT)

13.55 – 14.10  **Critical assessment of FDG-PET for bladder cancer staging:** For the better or for the worse?
L. Mertens, Amsterdam (NL)

14.10 – 14.25  **The sentinel node technique:** A dead horse in Urology?
H. Van der Poel, Amsterdam (NL)

14.25 – 14.30  Questions and answers
14.30 – 15.15 Poster session and best poster award
Moderators: P. Martino, Bari (IT)  
G. Salomon, Hamburg (DE)

Presentations will take place on stage. The presentations are 7 minutes in length, followed by 3 minutes of discussion.

14.30 – 14.40 Staging and restaging prostate cancer with Ga-68 PSMA PET-CT: Initial results of a contemporary cohort  
O. Acar, Istanbul (TR)

14.40 – 14.50 MRI can reduce the number of prostate biopsies after previous confirmatory biopsy in men on active surveillance for low-grade prostate cancer  
A. Alberts, Rotterdam (NL)

14.50 – 15.00 Targeted dual-modality imaging in renal cell carcinoma: An ex vivo kidney perfusion study  
M. Hekman, Nijmegen (NL)

15.00 – 15.10 Percutaneous 3T MR-guided cryoablation of small renal masses: Initial experience  
T. Van Oostenbrugge, Nijmegen (NL)

15.10 – 15.15 Best poster award

15.15 – 15.45 Coffee break and poster viewing

15.45 – 17.50 How can imaging individualise and optimise prostate cancer management?  
T. Loch, Flensburg (DE)  
V. Scattoni, Milan (IT)

All presentations are 7 minutes in length, followed by 3 minutes of discussion.

15.45 – 16.10 Point and counterpoint in prostate cancer imaging: MRI detects especially significant prostate cancers, myth or truth?  

15.45 – 15.55 Myth: J. Walz, Marseille (FR)  


16.05 – 16.10 Discussion

16.10 – 16.20 What is the new standard of prostate MRI? Mandatory sequences and PIRADS 2.0  
J.J. Futterer, Nijmegen (NL)

16.20 – 16.30 New perspectives of prostate ultrasound: Quantification of contrast enhanced ultrasound  
M. Mischi, Eindhoven (NL)

16.30 – 16.40 New perspectives of prostate ultrasound: Quantification with shearwave elastography  
G. Salomon, Hamburg (DE)

16.40 – 16.50 New perspectives of prostate ultrasound: Use of ANNA/C-TRUS for multiparametric ultrasound  
T. Loch, Flensburg (DE)

16.50 – 17.00 New perspectives of prostate ultrasound: Do we need an PIRADS score for ultrasound?  
A. Postema, Amsterdam (NL)
17.00 – 17.10  mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?  
V. Scattoni, Milan (IT)

17.10 – 17.20  Critical assessment of MRI in the local staging of prostate cancer  
M. De Rooij, Nijmegen (NL)

17.20 – 17.30  mpMRI in patients considered for active surveillance for prostate cancer  
A. Villers, Lille (FR)

17.30 – 17.40  Detection of bone metastasis: Is whole body MRI the new reference?  
V. Pasoglou, Brussels (BE)

17.40 – 17.50  Individualised treatment of metastatic prostate cancer: Monitoring of treatment response  
A. Padhani, Northwood (GB)

17.50 – 18.00  Summary and closure of the ESUI programme